Oppenheimer Remains Sidelined Following Endo Int'l's (ENDP) New CEO Appointment

Oppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP), following the company's announced appointment of Paul Campanelli to president and chief executive officer. Mr. Campanelli joined ENDP in 2015 through the acquisition of Par Pharmaceuticals and most recently served as the CEO of Par. Mr. Campanelli's appointment is effective immediately.

Analyst Marcus Ho commented, "Shares of Endo were up ~15% (vs. S&P 500 ~flattish) after the company announced the appointment of Paul V. Campanelli to president and chief executive officer, replacing former CEO Rajiv De Silva. We were not entirely surprised by the move as Endo has been especially hit hard by both the recent negative commentary surrounding opioids and the erosion in the generics pricing environment. We note shares of Endo have declined ~-18% since the end of 2Q16. Management reaffirmed 3Q and full-year 2016 guidance and is now directionally focused more on operational execution vs. business development, with an emphasis on pipeline and paragraph IV opportunities on the generics side and product development (e.g., Xiaflex) on the branded side. We maintain our Perform rating."

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $23.39 yesterday.

You May Also Be Interested In

• Tesla stock slides 5% as two key executives leave the company amid new layoffs
• Citizens Financial Group (CFG) Appoints Paul Casey as Head of Wealth Business
• Jefferies Downgrades Snap One Holdings (SNPO) to Hold